Hendricks Diane - 16 Dec 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
10%+ Owner
Signature
/s/ Quan Vu, Attorney-in-fact
Issuer symbol
MNPR
Transactions as of
16 Dec 2025
Net transactions value
$0
Form type
4
Filing time
17 Dec 2025, 15:42:31 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hendricks Diane 10%+ Owner 1000 SKOKIE BLVD SUITE 350, WILMETTE /s/ Quan Vu, Attorney-in-fact 17 Dec 2025 0001727478

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Other $0 -43,499 -7.1% $0.000000 567,580 16 Dec 2025 See footnote F1
holding MNPR Common Stock 93,750 16 Dec 2025 See footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Hendricks Diane is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Reported disposition relates to pro rata distribution by Gem Pharmaceuticals, LLC ("Gem") to its members in which the reporting person has no pecuniary interest. Pharma Investments LLC ("Pharma") owns a controlling share of Gem and the reporting person, a manager of Gem, owns a controlling share of Pharma, so Pharma and its controlling shareholders have indirect control over the securities described herein. The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein.
F2 This is based upon the 93,750 shares of Monopar Common Stock that DMH Business LLC directly owns. As a manager of DMH Business LLC, Ms. Hendricks may be deemed to share voting and dispositive power over these 93,750 shares. Ms. Hendricks disclaims beneficial ownership of the 93,750 shares held by DMH Business LLC, except to the extent of her pecuniary interest therein.